Therapy Areas: AIDS & HIV
Lyndra Therapeutics and Gilead Sciences to Collaborate on Development of Ultra-Long-Acting HIV Therapeutics
12 July 2019 - - US-based sustained-release therapies developer Lyndra Therapeutics has forged a partnership with US-based biopharmaceutical company Gilead Sciences, Inc. (NASDAQ: GILD) to develop and commercialise ultra-long-acting oral HIV therapies, the company said.
Gilead will have exclusive rights to Lyndra's therapeutics platform for ultra-long-acting formulations related to HIV.
Lyndra's ultra-long-acting dosage form has the potential to improve medication adherence by allowing patients to take a pill once a week, or even less frequently, rather than daily.
This partnership announcement comes just months after Gilead joined Lyndra's oversubscribed USD 60.9m series B financing round.
Lyndra Therapeutics' orally administered dosage form is designed to deliver sustained, steady-state release of one or more drugs for up to a week or longer while temporarily residing in the stomach.
Taking a single, long-acting pill weekly instead of daily or more often can improve medication adherence and health outcomes while reducing burdens on individuals and their caregivers.
Inside a familiar capsule is a star-shaped formulation with active pharmaceutical ingredients that are released consistently over time.
The formulation, which is designed to open once inside the stomach, eventually exits safely via the gastrointestinal tract, like undigested food.
Lyndra Therapeutics aims to improve healthcare outcomes through oral, ultra-long-acting, sustained-release therapies that change how people take medicines.
Instead of taking medications daily or more frequently, doses would be administered weekly or monthly, improving medication adherence for better health outcomes and lower healthcare costs.
Delivering controlled amounts of medicine would also reduce side effects and improve drug efficacy.